We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Large-Scale Genetic Study of Diabetes

By Biotechdaily staff writers
Posted on 06 Aug 2004
A genetic study of more than 2,000 people is being conducted by scientists at Cambridge University (UK) in an effort to better understand type 1 diabetes and discover disease-associated genes and polymorphisms.

Leading the research is Professor John Todd, of the Juvenile Diabetes Research Foundation at Cambridge. More...
His group will use a standard panel of 10,000 nonsynonymous single nucleotide polymorphisms (SNPs) to compare genotypes between 1,000 control samples and 1,000 diabetic samples. This is the first stage in an analysis of more than 20,000 DNA samples already collected from diabetes patients and their relatives.

Scientists will use the MegAllele genotyping reagents and software of ParAllele BioScience (South San Francisco, CA, USA) and the GeneChip Tag Arrays and instrumentation systems of Affymetrix (also in South San Francisco). A recent partnership between Affymetrix and ParAllele enables researchers to perform large-scale genotyping in their own labs with their own panels of SNPs. Users can select SNPs from custom panels of 3,000-5,000 SNPs and standard panels of up to 10,000 pre-selected SNPs. Assay design is customized and comprehensive, enabling users to successfully genotype more of the SNPs they want.

"This research project is the most exciting and important genetics experiment I've ever been involved in,” said Prof. Todd. "We've been collecting samples for quite some time now and have been waiting for a technology that would give us the genetic power we needed to commence informative studies. Using this new solution from Affymetrix and ParAllele for a genome-wide gene association study provides us with the best opportunity we've ever had to discover new disease-associated genes and polymorphisms.”




Related Links:
Cambridge Univ.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.